We advance microbiome-based innovations across therapeutics and functional health foods.
Our pipeline includes LT-001, which has completed a Phase 1 clinical trial, as well as HACO1 and ATG-K2,
probiotics that have received product-specific approval from Korea’s Ministry of Food and
Drug Safety for postprandial blood glucose control and body fat reduction.